Biodistribution of a potential chemotherapeutic, dinuclearbisphosphinogold(I) dithiocarbamate, as determined by its 198Au radiolabelled analogue
| Autor: | Zoltan Szucs, William Rae, Modisenyane Mongane, S Lamprecht, Frederik H. Kriel, Jan Rijn Zeevaart, Cornelius J. Bester, Johan A. van Staden |
|---|---|
| Přispěvatelé: | 10070095 - Bester, Cornelius Johannes Jacobus, 16951484 - Zeevaart, Jan Rijn, Kriel, Federik H, Szucs, Zoltan, Van Staden, Johan, Bester, Cornelius, Mongane, Modisenyane, Lamprecht, Sebastiaan, Rae, William, Zeevaart, Jan Rijn |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
198Au
Biodistribution Health Toxicology and Mutagenesis Spleen Gold(I) Analytical Chemistry medicine Radiology Nuclear Medicine and imaging Dithiocarbamate Spectroscopy chemistry.chemical_classification business.industry Radiolabelling Radiochemistry Public Health Environmental and Occupational Health Bisphosphine Pollution In vitro medicine.anatomical_structure Nuclear Energy and Engineering chemistry In vivo biodistribution Nuclear medicine business |
| Popis: | Dinuclearbisphosphinogold(I) dithiocarbamato, BPDTC, was previously found to have antitumour activity in vitro. 198Au radiolabelled BPDTC (radiochemical yield of 70 ± 6 % and radiochemical purity of[95 %) was used to determine its in vivo biodistribution in Sprague-Dawley rats. Gamma scintigraphs were performed over a period of 48 h and final radioactivity measurements of harvested organs of the test animals after termination was performed at 2, 4 and 48 h. The study successfully showed the biodistribution of the gold complex, with the highest uptake of the compound being observed in the lungs, liver and spleen Nuclear Technologies in Medicine and the Biosciences Initiative (NTeMBI), a national technology platform developed and managed by the South African Nuclear Energy Corporation (Necsa) and funded by the Department of Science and Technology. Biomed (Mintek) |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|